The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study Bob Djavan,

Slides:

Advertisements

Similar presentations

The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Advertisements

Pascal Rischmann European Urology Supplements

Reversible, Non-Barrier Male Contraception: Status and Prospects

Female Urinary Incontinence in the West of Turkey: Prevalence, Risk Factors and Impact on Quality of Life Izzet Kocak, Pinar Okyay, Mehmet Dundar, Haluk.

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Management of Acute and Chronic Retention in Men

Validity and Reliability of a Questionnaire for Evaluating Nocturia, Nocturnal Enuresis and Sleep-Interruptions in an Elderly Population M.H. Bing, L.A.

John P. Mulhall, Francesco Montorsi European Urology

Martin C. Michel European Urology Supplements

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

Volume 63, Issue 1, Pages (January 2013)

Volume 56, Issue 3, Pages (September 2009)

Impact of Nocturia on Sleep and Energy

Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers

A Novel Treatment of Premature Ejaculation

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Counselling the Prostate Cancer Patient

Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old P. Perrin,

An Update of Current Practice in Hypospadias Surgery

Treatment of Bacterial Urinary Tract Infections: Presence and Future

Richard C. Harkaway European Urology Supplements

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Neal Shore European Urology Supplements

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

Long-Term Hormonal Therapy: Who Would Benefit?

The Hallmarks of BPH Progression and Risk Factors

Sergio Bracarda European Urology Supplements

Pharmacotherapy in Stress and Mixed Incontinence

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

Christian Stief European Urology Supplements

European Urology is “Your” Journal

Preclinical Profile of Zoledronic Acid in Prostate Cancer Models

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

Martin Michel, Jean de la Rosette European Urology Supplements

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

Retrocaval Ureter—Magnetic Resonance Appearances

The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean

Richard Berges European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid Theresa A. Guise,

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

LUTS and Sexual Dysfunction: Implications for Management of BPH

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation Martin.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects Martin C. Michel, Cees Korstanje, Walter.

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Hormone Therapy: Improving Therapy Decisions and Monitoring

The Impact of Premature Ejaculation on Partners and Relationships

Emmanuel Chartier-Kastler, Andrea Tubaro European Urology Supplements

Diagnosis and Management of Cryptorchidism

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

Epidemiology and Demographics of Prostatitis

Jan Roigas European Urology Supplements

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

Michael Marberger European Urology Supplements

Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal European Urology.

Presentation transcript:

The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study Bob Djavan, Shirin Milani, Jonathan Davies, John Bolodeoku European Urology Supplements Volume 4, Issue 2, Pages 61-68 (February 2005) DOI: 10.1016/j.eursup.2004.12.001 Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 1 Main causes of disturbed sleep maintenance in elderly men aged 50–93 years [6]. European Urology Supplements 2005 4, 61-68DOI: (10.1016/j.eursup.2004.12.001) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 2 Tamsulosin pk profiles of tamsulosin OCAS steady state (study 617cl302) and tamsulosin modified release steady state (study YM12617). European Urology Supplements 2005 4, 61-68DOI: (10.1016/j.eursup.2004.12.001) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 3 Mean increase of hours of undisturbed sleep from baseline to endpoint (FAS). European Urology Supplements 2005 4, 61-68DOI: (10.1016/j.eursup.2004.12.001) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 4 Mean decrease in nocturnal voids from baseline to endpoint (FAS). European Urology Supplements 2005 4, 61-68DOI: (10.1016/j.eursup.2004.12.001) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 5 Effect of treatment on mean total I-PSS over time (FAS). European Urology Supplements 2005 4, 61-68DOI: (10.1016/j.eursup.2004.12.001) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 6 Mean decrease I-PSS nocturnia sub-score voids from baseline to endpoint (FAS). European Urology Supplements 2005 4, 61-68DOI: (10.1016/j.eursup.2004.12.001) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 7 Mean decrease I-PSS quality of life (QoL) from baseline to endpoint (FAS). European Urology Supplements 2005 4, 61-68DOI: (10.1016/j.eursup.2004.12.001) Copyright © 2004 Elsevier B.V. Terms and Conditions